Oxford COVID Vaccine Safe, Effective, Especially in Older Adults

Modesto Morganelli
Novembre 22, 2020

Scientists at the University of Oxford say their experimental COVID-19 vaccine shows a strong immune response among older people. Instead, it looked at safety indicators and the body's immune response.

Pharmaceutical companies around the world have been working on a COVID-19 vaccine since the early stages of the pandemic.

PAHO and UNICEF have already kicked off the purchasing process for COVID-19 vaccines by inviting vaccine manufacturers around the world to apply to become a supplier for the 186 countries that have joined the COVAX facility, which aims to deploy two billion doses of the vaccines globally.

This is China's first phase-3 efficacy study for a Recombinant subunit COVID-19 vaccine candidate, Anhui Zhifei Longcom Biopharmaceutical, said in a statement on Thursday.

Unlike the Pfizer-BioNTech and Moderna shots, both of which use new technology known as messenger RNA, AstraZeneca's is a viral vector vaccine made from a weakened version of a common cold virus found in chimpanzees. The human cells will then create proteins to develop antibodies against the coronavirus.

Working with drug-maker AstraZeneca, Oxford is now carrying out its Phase 3 study.

Jointly developed by the company and the Institute of Microbiology under the Chinese Academy of Sciences, the vaccine was issued a clinical research permit from the National Medical Products Administration on June 19.

Dr Reddy's Laboratories will soon start combined phase two and three trials of the Russian COVID-19 vaccine Sputnik V in India. Pollard said he expects to release all data from the Phase 3 study by late December.

We suspect that we will need as much help as we can get from PAHO which, fortunately, has been quite proactive in partnering with the Inter-American Development Bank, the European Union and other financial institutions and donors to secure the funding needed for lower income countries in the region to join COVAX.

"We're still waiting to get to the point where we can do the analysis to just work out how well the vaccine can protect people, and we're getting ever closer to that", he told journalists.

At the speed at which things are developing on the vaccine front, we don't have much time to, as Jamaicans on the street would say, lay-lay. Ashley Thompson was the editor.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE